Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic ...

CG Oncology has taken the ribbon for the first biotech initial public offering (IPO) of the new year and its $380 million raise – which far outstrips the proceeds forecast – backs up the view ...

Biotechnology is a broad discipline in which biological processes, organisms, cells or cellular components are exploited to develop new technologies. New tools and products developed by ...

UroGen Pharma (NASDAQ:URGN) on Thursday announced the acquisition of oncolytic virus ICVB-1042 and related assets from the preclinical-stage biotech IconOVir Bio for cash and stock in a deal worth ...

Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...

Germany’s Boehringer Ingelheim has made a move to expand its cancer pipeline via a takeover of T3 Pharma, a spinout from the University of Basel in Switzerland. The pharma group is paying CHF ...

Cash and Cash Equivalents: $15.9 million as of December 31, 2024. Net Cash Used in Operating Activities: $27 million for 2024, compared to $28.4 million for 2023. General and Administrative ...

Cash and Cash Equivalents: $15.9 million as of December 31, 2024. Net Cash Used in Operating Activities: $27 million for 2024, compared to $28.4 million for 2023. General and Administrative Expenses: ...